Amarin (AMRN) News Today $0.59 0.00 (-0.82%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$0.59 0.00 (-0.36%) As of 02/21/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Amarin Co. plc (NASDAQ:AMRN) Shares Acquired by Waterfront Wealth Inc.Waterfront Wealth Inc. increased its position in shares of Amarin Co. plc (NASDAQ:AMRN - Free Report) by 181.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,481,766 shares of the biopharmaceutical company's stock after acquiriFebruary 22 at 6:11 AM | marketbeat.comAmarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025February 19 at 8:30 AM | globenewswire.comFY2025 Earnings Estimate for Amarin Issued By Zacks ResearchAmarin Co. plc (NASDAQ:AMRN - Free Report) - Equities researchers at Zacks Research reduced their FY2025 earnings per share estimates for Amarin in a research note issued on Tuesday, February 11th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earFebruary 15, 2025 | marketbeat.comFY2025 EPS Estimates for Amarin Decreased by Zacks ResearchFebruary 15, 2025 | americanbankingnews.comAmarin (NASDAQ:AMRN) Stock Rating Upgraded by StockNews.comFebruary 13, 2025 | americanbankingnews.comAmarin (NASDAQ:AMRN) Raised to "Hold" at StockNews.comStockNews.com raised Amarin from a "sell" rating to a "hold" rating in a research note on Tuesday.February 11, 2025 | marketbeat.comLongitude Cayman Ltd. Sells 750,000 Shares of Amarin Co. plc (NASDAQ:AMRN)Longitude Cayman Ltd. cut its holdings in shares of Amarin Co. plc (NASDAQ:AMRN - Free Report) by 31.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,620,000 shares of the biopharmaceFebruary 11, 2025 | marketbeat.comAmarin (NASDAQ:AMRN) Stock Rating Lowered by StockNews.comStockNews.com downgraded Amarin from a "hold" rating to a "sell" rating in a research report on Friday.January 24, 2025 | marketbeat.comEuropean Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Gains 2% for WeekJanuary 24, 2025 | msn.comAmarin (NASDAQ:AMRN) Upgraded to Hold at StockNews.comStockNews.com raised shares of Amarin from a "sell" rating to a "hold" rating in a research report on Monday.January 13, 2025 | marketbeat.comFY2024 Earnings Estimate for Amarin Issued By Zacks ResearchAmarin Co. plc (NASDAQ:AMRN - Free Report) - Stock analysts at Zacks Research reduced their FY2024 EPS estimates for shares of Amarin in a research note issued to investors on Wednesday, January 8th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post eJanuary 13, 2025 | marketbeat.comAmarin (NASDAQ:AMRN) Coverage Initiated at StockNews.comStockNews.com initiated coverage on Amarin in a research report on Sunday. They set a "sell" rating for the company.January 5, 2025 | marketbeat.comStockNews.com Begins Coverage on Amarin (NASDAQ:AMRN)StockNews.com started coverage on Amarin in a research report on Saturday. They set a "hold" rating on the stock.December 28, 2024 | marketbeat.comAmarin (NASDAQ:AMRN) Now Covered by StockNews.comStockNews.com initiated coverage on Amarin in a report on Friday. They set a "hold" rating on the stock.December 20, 2024 | marketbeat.comAmarin Receives National Reimbursement for VAZKEPA® in ItalyDecember 16, 2024 | globenewswire.comAmarin Corporation plc: Amarin Appoints Peter Fishman Chief Financial OfficerDecember 14, 2024 | finanznachrichten.deAmarin Names Peter Fishman Finance ChiefDecember 14, 2024 | marketwatch.comAmarin Appoints Peter Fishman Chief Financial OfficerDecember 13, 2024 | globenewswire.comEuropean Equities Traded in the US as American Depositary Tread Water in Friday TradingDecember 6, 2024 | msn.comStockNews.com Downgrades Amarin (NASDAQ:AMRN) to SellStockNews.com lowered shares of Amarin from a "hold" rating to a "sell" rating in a research report on Wednesday.December 4, 2024 | marketbeat.comEuropean Equities Traded in the US as American Depositary Receipts Rising MondayNovember 26, 2024 | msn.comAmarin Corp (NASDAQ:AMRN) Stock, Insider Trading ActivityNovember 21, 2024 | benzinga.comAmarin announces to present additional analysis from REDUCE-IT outcomes trialNovember 12, 2024 | markets.businessinsider.comAmarin (NASDAQ:AMRN) Announces Earnings Results, Misses Expectations By $0.02 EPSAmarin (NASDAQ:AMRN - Get Free Report) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.02). Amarin had a negative net margin of 16.33% and a negative return on equity of 7.15%. The firm had revenue of $42.30 million during the quarter, compared to analysts' expectations of $43.82 million. During the same quarter in the prior year, the firm posted ($0.05) EPS.November 2, 2024 | marketbeat.comAmarin Corp PLC (AMRN) Q3 2024 Earnings Call Highlights: Navigating Revenue Declines Amid ...November 1, 2024 | finance.yahoo.comAmarin Corporation plc (NASDAQ:AMRN) Q3 2024 Earnings Call TranscriptNovember 1, 2024 | msn.comAmarin sees current cash, investments, other assets to support operationsOctober 31, 2024 | markets.businessinsider.comAmarin Corporation: Q3 Highlights and Future OutlookOctober 31, 2024 | markets.businessinsider.comAmarin Reports Third Quarter 2024 Financial Results and Provides Business UpdateOctober 31, 2024 | markets.businessinsider.comAmarin Plc (AMRN) Q3 2024 Earnings Call TranscriptOctober 31, 2024 | finance.yahoo.comAmarin (AMRN) Scheduled to Post Earnings on WednesdayAmarin (NASDAQ:AMRN) will be releasing earnings after the market closes on Wednesday, October 30, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=632333)October 23, 2024 | marketbeat.comAmarin Corp PLC (AMRN) Q2 2024 Earnings Call Highlights: Navigating Revenue Challenges and ...October 10, 2024 | uk.finance.yahoo.comAmarin Corp (NASDAQ:AMRN) Stock, Short Interest ReportOctober 4, 2024 | benzinga.comZacks Research Brokers Lift Earnings Estimates for Amarin Co. plc (NASDAQ:AMRN)Amarin Co. plc (NASDAQ:AMRN - Free Report) - Investment analysts at Zacks Research upped their FY2025 earnings per share (EPS) estimates for shares of Amarin in a report issued on Tuesday, October 1st. Zacks Research analyst R. Department now expects that the biopharmaceutical company will earn (October 4, 2024 | marketbeat.comAmarin Announces Two Upcoming Investor EventsOctober 1, 2024 | markets.businessinsider.comHere's Why We're Not At All Concerned With Amarin's (NASDAQ:AMRN) Cash Burn SituationSeptember 18, 2024 | finance.yahoo.comAura Biosciences: Highly Derisked Late-Stage Eye Cancer CompanySeptember 17, 2024 | seekingalpha.comResearch Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) MeetingSeptember 9, 2024 | globenewswire.comAmarin Corp PLC (EH3A.DU)September 4, 2024 | sg.finance.yahoo.comAmarin Co. plc Expected to Post Q3 2024 Earnings of ($0.05) Per Share (NASDAQ:AMRN)Amarin Co. plc (NASDAQ:AMRN - Free Report) - Analysts at Zacks Research raised their Q3 2024 earnings per share estimates for Amarin in a research report issued on Wednesday, August 21st. Zacks Research analyst R. Department now expects that the biopharmaceutical company will earn ($0.05) per shaAugust 26, 2024 | marketbeat.comLatest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) CongressAugust 22, 2024 | globenewswire.comAmarin Corp (NASDAQ:AMRN) Stock Quotes, Forecast and News SummaryAugust 17, 2024 | benzinga.comAmarin Co. plc (NASDAQ:AMRN) CEO Aaron Berg Buys 160,000 SharesAugust 6, 2024 | insidertrades.comAmarin Co. plc (NASDAQ:AMRN) CEO Purchases $102,400.00 in StockAmarin Co. plc (NASDAQ:AMRN - Get Free Report) CEO Aaron Berg acquired 160,000 shares of the stock in a transaction dated Friday, August 2nd. The shares were purchased at an average price of $0.64 per share, for a total transaction of $102,400.00. Following the completion of the transaction, the chief executive officer now owns 805,380 shares of the company's stock, valued at approximately $515,443.20. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.August 5, 2024 | marketbeat.comAmarin’s Stock Maintains Hold Rating Amidst Revenue Highs and Market ChallengesAugust 5, 2024 | markets.businessinsider.comBrokers Set Expectations for Amarin Co. plc's FY2024 Earnings (NASDAQ:AMRN)Amarin Co. plc (NASDAQ:AMRN - Free Report) - Research analysts at Cantor Fitzgerald lifted their FY2024 earnings per share estimates for Amarin in a report issued on Thursday, August 1st. Cantor Fitzgerald analyst L. Chen now expects that the biopharmaceutical company will earn ($0.13) per shareAugust 5, 2024 | marketbeat.comFY2026 EPS Estimates for Amarin Co. plc (NASDAQ:AMRN) Decreased by AnalystAmarin Co. plc (NASDAQ:AMRN - Free Report) - Analysts at Zacks Research reduced their FY2026 earnings per share (EPS) estimates for shares of Amarin in a report released on Tuesday, July 30th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will post earninAugust 1, 2024 | marketbeat.comAmarin’s Sell Rating Upheld Amid Revenue Concerns and Market Access ChallengesAugust 1, 2024 | markets.businessinsider.comAmarin appoints new CEO and grants stock optionsJuly 31, 2024 | investing.comAmarin Corporation plc (AMRN) Q2 2024 Earnings Call TranscriptJuly 31, 2024 | seekingalpha.com Get Amarin News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address AMRN Media Mentions By Week AMRN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AMRN News Sentiment▼0.210.60▲Average Medical News Sentiment AMRN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AMRN Articles This Week▼32▲AMRN Articles Average Week Get Amarin News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AbCellera Biologics News Replimune Group News Collegium Pharmaceutical News Rocket Pharmaceuticals News Evolus News Pharvaris News ArriVent BioPharma News Cogent Biosciences News Oculis News Bicycle Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AMRN) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amarin Co. plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Amarin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AMRN Stock Alerts